DYN — Dyne Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.26bn
- $614.52m
- 31
- 23
- 12
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2 | ||
| Price to Tang. Book | 2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.99% | ||
| Return on Equity | -88.03% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 0.91 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Directors
- Jason Rhodes CHM (52)
- Joshua Brumm PRE
- Susanna High COO (53)
- Ashish Dugar SVP
- Oxana Beskrovnaya CSO (60)
- Richard Scalzo VPR (35)
- Jonathan McNeill VPR (36)
- Wildon Farwell OTH (46)
- Catherine Stehman-Breen DRC (58)
- Edward Hurwitz IND (57)
- Dirk Kersten IND (46)
- Lawrence Klein IND (38)
- David Lubner IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 28th, 2013
- Public Since
- September 17th, 2020
- No. of Shareholders
- 10
- No. of Employees
- 191
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 113,633,782
- Address
- 1560 Trapelo Road, WALTHAM, 02451
- Web
- https://dyne-tx.com/
- Phone
- +1 7817868230
- Contact
- Amy Reilly
- Auditors
- Deloitte & Touche LLP
Upcoming Events for DYN
Dyne Therapeutics Inc Annual Shareholders Meeting
Dyne Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Dyne Therapeutics Inc Earnings Release
Similar to DYN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Dyne Therapeutics share price?
As of Today at 20:20 UTC, shares in Dyne Therapeutics are trading at $11.06. This share price information is delayed by 15 minutes.
How has the Dyne Therapeutics share price performed this year?
Shares in Dyne Therapeutics last closed at $11.06 and the price had moved by -53.32% over the past 365 days. In terms of relative price strength the Dyne Therapeutics share price has underperformed the S&P500 Index by -56.92% over the past year.
What are the analyst and broker recommendations for Dyne Therapeutics?
The overall consensus recommendation for Dyne Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Dyne Therapeutics dividend yield?
Dyne Therapeutics does not currently pay a dividend.
Does Dyne Therapeutics pay a dividend?
Dyne Therapeutics does not currently pay a dividend.
When does Dyne Therapeutics next pay dividends?
Dyne Therapeutics does not currently pay a dividend.
How do I buy Dyne Therapeutics shares?
To buy shares in Dyne Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dyne Therapeutics?
As of the previous close price of $11.06, shares in Dyne Therapeutics had a market capitalisation of $1.26bn.
Where are Dyne Therapeutics shares listed?
Here are the trading details for Dyne Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DYN
What kind of share is Dyne Therapeutics?
Based on an overall assessment of its quality, value and momentum Dyne Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dyne Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Dyne Therapeutics is $50.62. That is 357.69% above the last closing price of $11.06.
Analysts covering Dyne Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.60 for the next financial year.
Find out moreWhat is the trend in the Dyne Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dyne Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -62.07%.
As of the last closing price of $11.06, shares in Dyne Therapeutics were trading -57.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dyne Therapeutics PE Ratio?
The Dyne Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dyne Therapeutics?
Dyne Therapeutics' management team is headed by:
- Jason Rhodes - CHM
- Joshua Brumm - PRE
- Susanna High - COO
- Ashish Dugar - SVP
- Oxana Beskrovnaya - CSO
- Richard Scalzo - VPR
- Jonathan McNeill - VPR
- Wildon Farwell - OTH
- Catherine Stehman-Breen - DRC
- Edward Hurwitz - IND
- Dirk Kersten - IND
- Lawrence Klein - IND
- David Lubner - IND